TIKRs estimates table shows consensus EPS of $2.90 for the June 2026 quarter up around 14% year-over-year stepping to $3.12 for the March 2027 quarter, a trajectory that assumes sustained high-single-digit revenue growth compounds into faster earnings growth as SG&A scales
GLP-1R expressed in the nucleus tractus solitarius signals to suppress appetite, delay gastric emptying and reduce body weight, and this is proposed to be mediated through PKA, decreasing phosphorylation of AMPK (22, 89, 110)
Clinical results show eye bag volume improvement up to 156.67%, under-eye wrinkle improvement up to 121.32%, under-eye volume enhancement up to 154.45%, and dark circle brightening up to 103.95% after use
There is no doubt that GLP-1 medications for weight loss are changing the game in terms of how we view and treat obesity, weight loss and even plastic surgery